title: Development of dendritic-cell based prostate cancer vaccine.
abstract: Available treatments for metastatic prostate cancer have failed to demonstrate significant curative potential. Current efforts are now directed towards developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunotherapeutic strategies utilize patient immune system components to kill cancer cells. This review discusses progress in active specific immunotherapeutic approaches as potential alternative methods in the treatment of metastatic prostate cancer. One of the newest advances in cancer immunotherapy is the use of dendritic cells as the vehicle to deliver cancer antigens for an effective in vivo T cell activation. The development of dendritic cell-based prostate cancer vaccine, as well as results of several clinical trials in prostate cancer involving the administration of peptide-pulsed autologous dendritic cell pulsed are discussed.
authors.affiliation: Pacific Northwest Cancer Foundation, 13758 Lake City Way NE, Suite 200, Seattle, WA 98125, USA. benhenry@uswest.net
authors.forename: B A
authors.initials: BA
authors.lastname: Tjoa
authors.forename: G P
authors.initials: GP
authors.lastname: Murphy
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects; D015703:Antigens, CD / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D019496:Cancer Vaccines / Q000009:adverse effects / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D006801:Humans; D016233:Immunotherapy, Active / Q000009:adverse effects; D008297:Male; D008562:Membrane Glycoproteins / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D008562:Membrane Glycoproteins